The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
CD3-specific monoclonal antibodies were the first rodent monoclonals introduced in clinical practice in the mid 1980s as approved immunosuppressants to prevent and treat organ allograft rejection. Since then compelling evidence has been accumulated to suggest that in addition to their immunosuppressive properties, CD3-specific antibodies can also afford inducing immune tolerance especially in the context of ongoing immune responses. Thus, they are highly effective at restoring self-tolerance in overt autoimmunity, a capacity first demonstrated in the experimental setting, which was recently transferred to the clinic with success.
Chatenoud
L
L
Université René Descartes, Paris, France. chatenoud@necker.fr
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D004195:Disease Models, Animal; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007108:Immune Tolerance; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007004:Hypoglycemic Agents